Briefcase Email Alerts Downloads Snapshot RSS Email Printed Materials Print this page

Achieve

Press Releases


 
Press Releases
  Date Title and Summary View
Jun 24, 2008
CAMBRIDGE, Mass. and CARLSBAD, Calif., June 24, 2008 – Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA (miRNA) therapeutics, announced today that it has been named to the annual ...
May 6, 2008
CAMBRIDGE, Mass. and CARLSBAD, Calif., May 6, 2008 – Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA (miRNA) therapeutics, announced today that it has obtained exclusive rights from Stanford U...
Apr 17, 2008
LONDON, United Kingdom, PHILADELPHIA, Penn. and CARLSBAD, Calif., April 17, 2008 – GlaxoSmithKline (GSK) and Regulus Therapeutics LLC (Regulus) today announced a worldwide strategic alliance to discover, develop and market novel microRNA-targeted therapeutics to treat inflammatory diseases such as rheumatoid arthritis and inflammatory bowe...
Feb 11, 2008
CAMBRIDGE, Mass. and CARLSBAD, Calif., February 11, 2008 – Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA therapeutics, announced today the appointment of Peter S. Linsley, Ph.D., as Chief Sc...
Oct 31, 2005
CAMBRIDGE, Mass., October 31, 2005 – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today the publication of a novel approach to regulate gene expression through the silencing of microRNAs (miRNAs). miRNAs have been shown to regulate a large number of genes in the human genome through the RNAi pat...
Sep 13, 2005
CAMBRIDGE, Mass. & CARLSBAD, Calif.–(BUSINESS WIRE)–Sept. 13, 2005–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today a co-exclusive license agreement with Stanford University related to the discovery and development of therapeutic products for hepatitis C virus (HCV) ...
Oct 19, 2004
Intellectual Property From Max Planck Society Strengthens Companies’ Leadership Positions In RNA-Based Drug Discovery and Development CAMBRIDGE, Mass., and CARLSBAD, Calif., Oct. 19 /PRNewswire-FirstCall/ — Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Isis Pharmaceuticals, Inc. ...
Page: FirstPrevious ...
21
= add release to Briefcase